Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: epidermal growth-factor receptor
Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer
Currently, no treatment exists for lung cancer patients with epidermal growth-factor receptor (EGFR) mutation who have failed tyrosine kinase inhibitors, getifinib (Iressa) or erlotinib (Tarceva). However, an investigational drug, afatinib (BIBW 2992), was recently found to increase progression-free survival and … Continue reading
Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer
Tagged Afatinib, epidermal growth-factor receptor, erlotinib, getifinib, Iressa, Lung Cancer, Non small cell lung cancer, NSCLC, platinum, progression-free survival, Tarceva, time to tumor progression, tumor shrinkage
Comments Off on Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer
Gefitinib (Iressa) is better than Standard Therapy in Lung Cancer with EGFR Mutations
Gefitinib (Iressa) is more effective than first-line therapy in improving survival without disease in patients with advanced nonsmall-cell lung cancer (NSCLC) and epidermal growth-factor receptor (EGFR) mutations. The current study was conducted in 230 patients from 43 centers in Japan, … Continue reading
Posted in Lung Cancer, Non Small Cell Lung Cancer
Tagged carboplatin, EGFR, epidermal growth-factor receptor, gefitinib, Iressa, Lung Cancer, mutations, Non small cell lung cancer, paclitaxel, Survival
Comments Off on Gefitinib (Iressa) is better than Standard Therapy in Lung Cancer with EGFR Mutations
